WilliamJamesMaplesMD

PubMed

• 3 citations
  Results from the National Taskforce for Humanity in Healthcare's Integrated, Organizational Pilot Program to Improve Well-Being
  Read Pierce, William J. Maples, Jennifer Krippner, J. Bryan Sexton, Pam Adams, Theresa Amerson, Adam Breslow, David M. Clark, Ronald Paulus, M. Bridget Duffy> ;Joint Commission Journal on Quality and Patient Safety. 2021 Jun 7
• 15 citations
  An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer
  Keith C. Bible, Michael E. Menefee, Chia Chi Josh Lin, Michael Millward, William J. Maples, Boon Cher Goh, Nina J. Karlin, Madeleine A. Kane, Douglas Adkins, Julian R....> ;Thyroid. 2020 Sep 8
• 12 citations
  Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).
  Jesus Vera Aguilera, Ravi D. Rao, Jacob B. Allred, Vera J. Suman, Harold E. Windschitl, Judith S. Kaur, William J. Maples, Val J. Lowe, Edward T. Creagan, Lori A. Eric...> ;The Oncologist. 2018 Aug 1
• 5 citations
  Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation ...
  Scott H. Okuno, Ivy A. Petersen, Thomas C. Shives, Michelle R. Mahoney, Michael G. Haddock, Franklin H. Sim, Mary I. O'Connor, Svetomir N. Markovic, William J. Maples> ;American Journal of Clinical Oncology. 2016 Apr 1
• 11 citations
  Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors
  Jonathan R. Strosberg, George A. Fisher, Al B. Benson, Lowell B. Anthony, Bulent Arslan, John F. Gibbs, Edward W Greeno, Renuka Iyer, Michelle K. Kim, William J. Maple...> ;World Journal of Gastroenterology. 2015 Feb 28
• 12 citations
  Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consor...
  Jaime R. Merchan, Rui Qin, Henry C. Pitot, Joel Picus, Glenn Liu, Tom R. Fitch, William J. Maples, Patrick J. Flynn, Briant Fruth, Charles Erlichman> ;Cancer Chemotherapy and Pharmacology. 2015 Jan 3
• 33 citations
  Phase II Study of Temozolomide (TMZ) and Everolimus (RAD001) Therapy for Metastatic Melanoma: A North Central Cancer Treatment Group Study, N0675
  Roxana S. Dronca, Jacob B. Allred, Domingo G. Perez, Wendy K. Nevala, Elizabeth Ann T. Lieser, Michael A. Thompson, William J. Maples, Edward T. Creagan, Barbara A. Po...> ;American Journal of Clinical Oncology. 2014 Aug 1
• 78 citations
  A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H
  Keith C. Bible, Vera J. Suman, Julian R. Molina, Robert C. Smallridge, William J. Maples, Michael E. Menefee, Joseph Rubin, Nina J. Karlin, Kostandinos Sideras, John C...> ;The Journal of Clinical Endocrinology and Metabolism. 2014 Feb 25
• Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process.
  Strosberg, J. R.,Fisher, G. A.,Benson, A. B.,Malin, J. L.,Cherepanov, D.,Broder, M. S.,Anthony, L. B.,Arslan, B.,Fisher, G. A.,Gibbs, J. F.,Greeno, E.,Iyer, R. V.,Kim,...> ;Pancreas. 2013 Apr
• Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
  Galanis E, Markovic SN, Suman VJ, Nuovo GJ, Vile RG, Kottke TJ, Nevala WK, Thompson MA, Lewis JE, Rumilla KM, Roulstone V, Harrington K, Linette GP, Maples WJ, Coffey ...> ;Mol. Ther.. 2012-10-01
• 39 citations
  A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261
  Keith C. Bible, Prema P. Peethambaram, Ann L. Oberg, William J. Maples, David L. Groteluschen, Matthew P. Boente, Jill K. Burton, Leigh C. Gomez Dahl, Jennifer D. Tibo...> ;Gynecologic Oncology. 2012 Oct 1
• 118 citations
  A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
  Keith C. Bible, Vera J. Suman, Michael E. Menefee, Robert C. Smallridge, Julian R. Molina, William J. Maples, Nina J. Karlin, Anne M. Traynor, Priya Kumar, Boon Cher G...> ;The Journal of Clinical Endocrinology and Metabolism. 2012 Jul 6
• 4 citations
  Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.
  Bible, K., Smallridge, R., Morris, J., Molina, J., Suman, V., Copland, J., Rubin, J., Menefee, M., Sideras, K., Maples, W., McIver, B., Fatourechi, V., Hay, I., Foote,...> ;The American Journal of Managed Care. 2012 May 1
• 6 citations
  Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.
  Bible, K., Smallridge, R., Morris, J., Molina, J., Suman, V., Copland, J., Rubin, J., Menefee, M., Sideras, K., Maples, W., McIver, B., Fatourechi, V., Hay, I., Foote,...> ;Journal of Oncology Practice. 2012 May 1
• 15 citations
  Hepatic Arterial Infusion and Systemic Chemotherapy after Multiple Metastasectomy in Patients with Colorectal Carcinoma Metastatic to the Liver: A North Central Cancer...
  John S. Bolton, Michael J. O'Connell, Michelle R. Mahoney, Gist H. Farr, Tom R. Fitch, William J. Maples, David M. Nagorney, Joseph Rubin, Jyotsna Fuloria, Preston D. ...> ;Clinical Colorectal Cancer. 2012 Mar 1
• 66 citations
  A phase 2 study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C).
  Scott H. Okuno, Howard H. Bailey, Michelle R. Mahoney, Douglas Adkins, William J. Maples, Tom R. Fitch, David S. Ettinger, Charles Erlichman, Jann N. Sarkaria> ;Cancer. 2011 Aug 1
• Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
  Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Maples WJ, Picus J, Erlichman C> ;J. Clin. Oncol.. 2011-05-20
• A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.
  Attia S, Mahoney MR, Okuno SH, Adkins D, Ahuja HG, Ducker TP, Maples WJ, Ochs L, Wentworth-Hartung NL, Erlichman C, Bailey HH> ;J. Clin. Oncol.. 2011-05-20
• 315 citations
  Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
  Keith C. Bible, Vera J. Suman, Julian R. Molina, Robert C. Smallridge, William J. Maples, Michael E. Menefee, Joseph Rubin, Kostandinos Sideras, John C. Morris, Bryan ...> ;The Lancet. Oncology. 2010 Oct 1
• 122 citations
  NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus).
  Alexandria T. Phan, Kjell Öberg, Junsung Choi, Lynn H. Harrison, Manal M. Hassan, Jonathan R. Strosberg, Eric P. Krenning, Walter Kocha, Eugene A. Woltering, William J...> ;Pancreas. 2010 Aug 1
• 189 citations
  The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rec...
  Lowell Anthony, Jonathan R. Strosberg, David S. Klimstra, William J. Maples, Thomas M. O'Dorisio, Richard R.P. Warner, Gregory A. Wiseman, Al B. Benson, Rodney F. Pommier> ;Pancreas. 2010 Aug 1
• 29 citations
  A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: A phase 2 consortium study
  Gary A. Croghan, Vera J. Suman, William J. Maples, Mark R. Albertini, Gerald P. Linette, Lawrence E. Flaherty, John R. Eckardt, Cynthia X. Ma, Svetomir N. Markovic, Ch...> ;Cancer. 2010 Jul 15
• 18 citations
  Quality: the Mayo Clinic approach.
  Stephen J. Swensen, James A. Dilling, Dawn S. Milliner, Richard S. Zimmerman, William J. Maples, Mark E. Lindsay, George B. Bartley> ;American Journal of Medical Quality. 2009 Jul 7
• Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients.
  Merchan JR, Pitot HC, Qin R, Liu G, Fitch TR, Picus J, Maples WJ, Erlichman C> ;J. Clin. Oncol.. 2009-05-20
• Phase II trial of pazopanib in progressive, metastatic, iodine-insensitive differentiated thyroid cancers.
  Bible KC, Smallridge RC, Maples WJ, Molina JR, Menefee ME, Suman VJ, Burton JK, Bieber CC, Ivy SP, Erlichman C> ;J. Clin. Oncol.. 2009-05-20
• Join now to see all